These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

117 related items for PubMed ID: 2131050

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Antitumor activity of 2,2'-bipyridyl-6-carbothioamide: a ribonucleotide reductase inhibitor.
    Nocentini G, Barzi A.
    Gen Pharmacol; 1997 Nov; 29(5):701-6. PubMed ID: 9347313
    [Abstract] [Full Text] [Related]

  • 3. 2,2'-Bipyridyl-6-carbothioamide and its ferrous complex: their in vitro antitumoral activity related to the inhibition of ribonucleotide reductase R2 subunit.
    Nocentini G, Federici F, Franchetti P, Barzi A.
    Cancer Res; 1993 Jan 01; 53(1):19-26. PubMed ID: 8416745
    [Abstract] [Full Text] [Related]

  • 4. The 2,2'-bipyridyl-6-carbothioamide copper (II) complex differs from the iron (II) complex in its biochemical effects in tumor cells, suggesting possible differences in the mechanism leading to cytotoxicity.
    Nocentini G, Barzi A.
    Biochem Pharmacol; 1996 Jul 12; 52(1):65-71. PubMed ID: 8678909
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. 2,2'-Bipyridyl-6-carbothioamide derivatives as potential antitumor agents.
    Antonini I, Cristalli G, Franchetti P, Grifantini M, Martelli S, Filippeschi S.
    Farmaco Sci; 1986 May 12; 41(5):346-54. PubMed ID: 3720944
    [Abstract] [Full Text] [Related]

  • 7. Implications and problems in analysing cytotoxic activity of hydroxyurea in combination with a potential inhibitor of ribonucleotide reductase.
    Nocentini G, Barzi A.
    Pharmacol Res; 1990 May 12; 22 Suppl 1():39-40. PubMed ID: 2284243
    [No Abstract] [Full Text] [Related]

  • 8. 2,2'-Bipyridyl-6-carboxamidoximes with potential antitumor and antimicrobial properties.
    Cristalli G, Franchetti P, Grifantini M, Ripa S.
    Farmaco Sci; 1986 Jul 12; 41(7):499-507. PubMed ID: 3743743
    [Abstract] [Full Text] [Related]

  • 9. Sensitization of P388 murine leukemia cells to hydroxyurea cytotoxicity by hydrophobic iron-chelating agents.
    Satyamoorthy K, Chitnis M, Basrur V.
    Anticancer Res; 1986 Jul 12; 6(2):329-33. PubMed ID: 3518597
    [Abstract] [Full Text] [Related]

  • 10. N*-N*-S* tridentate ligand system as potential antitumor agents.
    Antonini I, Claudi F, Cristalli G, Franchetti P, Grifantini M, Martelli S.
    J Med Chem; 1981 Oct 12; 24(10):1181-4. PubMed ID: 7328579
    [Abstract] [Full Text] [Related]

  • 11. Characterization of mouse leukemia L1210 cells resistant to the ribonucleotide reductase inhibitor 4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone.
    Cory AH, Sato A, Thompson DP, Cory JG.
    Oncol Res; 1996 Oct 12; 8(10-11):449-56. PubMed ID: 9114437
    [Abstract] [Full Text] [Related]

  • 12. Inhibition of ribonucleotide reductase by a new class of isoindole derivatives: drug synergism with cytarabine (Ara-C) and induction of cellular apoptosis.
    Nandy P, Lien EJ, Avramis VI.
    Anticancer Res; 1999 Oct 12; 19(3A):1625-33. PubMed ID: 10470093
    [Abstract] [Full Text] [Related]

  • 13. Differential effect of collaterally sensitive antimetabolites on P388 murine leukemia sensitive and resistant to adriamycin in vitro.
    Satyamoorthy K, Deshpande SS, Chitnis MP.
    Neoplasma; 1989 Oct 12; 36(6):673-83. PubMed ID: 2515459
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Gold(III) complexes with bipyridyl ligands: solution chemistry, cytotoxicity, and DNA binding properties.
    Marcon G, Carotti S, Coronnello M, Messori L, Mini E, Orioli P, Mazzei T, Cinellu MA, Minghetti G.
    J Med Chem; 2002 Apr 11; 45(8):1672-7. PubMed ID: 11931621
    [Abstract] [Full Text] [Related]

  • 18. In vivo development and in vitro characterization of a subclone of murine P388 leukemia resistant to bis(diphenylphosphine)ethane.
    Hoke GD, McCabe FL, Faucette LF, Bartus JO, Sung CM, Jensen BD, Heys JR, Rush GF, Alberts DW, Johnson RK.
    Mol Pharmacol; 1991 Jan 11; 39(1):90-7. PubMed ID: 1898982
    [Abstract] [Full Text] [Related]

  • 19. Down-regulation of deoxycytidine kinase in human leukemic cell lines resistant to cladribine and clofarabine and increased ribonucleotide reductase activity contributes to fludarabine resistance.
    Månsson E, Flordal E, Liliemark J, Spasokoukotskaja T, Elford H, Lagercrantz S, Eriksson S, Albertioni F.
    Biochem Pharmacol; 2003 Jan 15; 65(2):237-47. PubMed ID: 12504799
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.